Physician profile
Scott E Janus
NPI 1841608049
$7,342.23
in general payments reported to CMS, 2019-2025
34 companies · $804 in 2025
The $804 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $681 · 2021: $1,157 · 2022: $1,549 · 2023: $1,728 · 2024: $901 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383 · Travel and Lodging: $836 · Consulting Fee: $150 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.91 |
| Travel and Lodging | $835.97 |
| Consulting Fee | $150.00 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $985.97 | 2023 | |
| Medtronic, INC. | $682.38 | 2021-2024 | Onyx Frontier, Resolute Onyx |
| Abbott Laboratories | $652.12 | 2019-2024 | Pressurewire, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $580.40 | 2019-2023 | Lifevest |
| Amgen INC. | $500.79 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $467.56 | 2019-2024 | Xarelto |
| Pfizer INC. | $436.27 | 2019-2025 | |
| Heartflow, INC. | $394.54 | 2024-2025 | |
| Novo Nordisk INC | $366.30 | 2023-2025 | Wegovy, Ozempic |
| Boston Scientific Corporation | $343.92 | 2023-2025 | Opticross, Watchman Access System |
| Medtronic Vascular, INC. | $336.46 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $242.13 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $168.76 | 2019-2024 | Farxiga |
| Cardiovascular Systems INC. | $148.00 | 2022 | |
| Alnylam Pharmaceuticals INC. | $125.25 | 2025 | Onpattro |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $95.06 | 2024-2025 | |
| Astellas Pharma US INC | $79.99 | 2021 | |
| Chiesi USA, INC. | $79.02 | 2022 | |
| Terumo Medical Corporation | $68.30 | 2022 | |
| Abiomed | $62.15 | 2019-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.42 | 2020-2022 | |
| Lantheus Medical Imaging, INC. | $49.81 | 2019 | |
| Alexion Pharmaceuticals, INC. | $42.12 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $34.30 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $33.74 | 2020-2021 | |
| Lundbeck LLC | $32.90 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $32.83 | 2024 | Opsumit, Uptravi |
| Cvrx, INC. | $21.71 | 2024 | Barostim Neo System |
| Sandoz INC. | $20.56 | 2023 | Treprostinil |
| Kiniksa Pharmaceuticals, Ltd. | $20.35 | 2021 | |
| Genzyme Corporation | $18.73 | 2019 | |
| Scpharmaceuticals INC. | $15.74 | 2023 | |
| Merck Sharp & Dohme LLC | $14.92 | 2021 | |
| Portola Pharmaceuticals, LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Janus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.